[Hypoxia in hepatocellular carcinoma]
- PMID: 17380070
[Hypoxia in hepatocellular carcinoma]
Abstract
Hepatocellular carcinoma (HCC) is characterized by hypervascularity, indicating that angiogenesis plays a vital role in HCC growth and progression. A number of anti-angiogenic therapies are being utilized in clinical trials in patients with HCC. However, the therapeutic efficacy of anti-angiogenic monotherapy is still insufficient. While inhibition of angiogenesis results in tumor hypoxia and cell death, this inhibition may also activate hypoxia-induced cell signals that may promote HCC progression. Therefore, an understanding of these signals may be essential in designing efficient anti-angiogenic therapies. This review summarizes the role of hypoxia-induced signals in HCC.
Similar articles
-
Angiogenesis and antiangiogenic therapy in hepatocellular carcinoma.Cancer Lett. 2006 Oct 28;242(2):151-67. doi: 10.1016/j.canlet.2006.01.008. Epub 2006 Mar 27. Cancer Lett. 2006. PMID: 16564617 Review.
-
Angiogenesis and anti-angiogenesis in hepatocellular carcinoma.Cancer Treat Rev. 2006 Oct;32(6):437-44. doi: 10.1016/j.ctrv.2006.06.002. Epub 2006 Jul 25. Cancer Treat Rev. 2006. PMID: 16870349 Review.
-
Vascular changes in hepatocellular carcinoma.Anat Rec (Hoboken). 2008 Jun;291(6):721-34. doi: 10.1002/ar.20668. Anat Rec (Hoboken). 2008. PMID: 18484619 Review.
-
Hypoxia and hepatocellular carcinoma: The therapeutic target for hepatocellular carcinoma.J Gastroenterol Hepatol. 2007 Aug;22(8):1178-82. doi: 10.1111/j.1440-1746.2007.04997.x. Epub 2007 Jun 7. J Gastroenterol Hepatol. 2007. PMID: 17559361 Review.
-
Molecular targeted therapies in hepatocellular carcinoma.Semin Oncol. 2012 Aug;39(4):486-92. doi: 10.1053/j.seminoncol.2012.05.005. Semin Oncol. 2012. PMID: 22846865 Review.
Cited by
-
The role of hypoxia inducible factor-1 in hepatocellular carcinoma.Biomed Res Int. 2014;2014:409272. doi: 10.1155/2014/409272. Epub 2014 Jul 2. Biomed Res Int. 2014. PMID: 25101278 Free PMC article. Review.
-
β-Patchoulene represses hypoxia-induced proliferation and epithelial-mesenchymal transition of liver cancer cells.Bioengineered. 2022 May;13(5):11907-11922. doi: 10.1080/21655979.2022.2065945. Bioengineered. 2022. PMID: 35546067 Free PMC article.
-
Bufalin suppresses hepatocellular carcinoma invasion and metastasis by targeting HIF-1α via the PI3K/AKT/mTOR pathway.Oncotarget. 2016 Apr 12;7(15):20193-208. doi: 10.18632/oncotarget.7935. Oncotarget. 2016. PMID: 26958938 Free PMC article.
-
FSCN‑1 increases doxorubicin resistance in hepatocellular carcinoma through promotion of epithelial-mesenchymal transition.Int J Oncol. 2018 May;52(5):1455-1464. doi: 10.3892/ijo.2018.4327. Epub 2018 Mar 20. Int J Oncol. 2018. PMID: 29568938 Free PMC article.
-
Hypoxia-inducible MiR-182 promotes angiogenesis by targeting RASA1 in hepatocellular carcinoma.J Exp Clin Cancer Res. 2015 Jun 28;34(1):67. doi: 10.1186/s13046-015-0182-1. J Exp Clin Cancer Res. 2015. PMID: 26126858 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical